Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors After Radical Surgery

NCT07594964 is registered in ClinicalTrials.gov with Shenzhen Xinhe Biomedical as lead sponsor.

NCT NCT07594964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07594964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors After Radical Surgery
Lead sponsor
Shenzhen Xinhe Biomedical
Phase
Phase 1
Overall status
Recruiting
Start date
August 25, 2025
Completion date
June 30, 2030
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

biliary cancer (cholangiocarcinoma, gall bladder cancer), gastric cancer (gc), hepatocellular carcinoma (hcc), pancreatic ductal adenocarcinoma (pdac)